Trial Profile
A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Foslinanib (Primary)
- Indications Cancer; Leukaemia; Lymphoma; Multiple myeloma; Solid tumours
- Focus Adverse reactions
- Sponsors TaiRx
- 07 May 2020 Status changed from active, no longer recruiting to completed.
- 14 Feb 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Mar 2020.
- 10 Sep 2019 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.